| Literature DB >> 18313930 |
Yasutomi Asano1, Shuji Kitamura, Taiichi Ohra, Fumio Itoh, Masahiro Kajino, Tomoko Tamura, Manami Kaneko, Shota Ikeda, Hideki Igata, Tomohiro Kawamoto, Satoshi Sogabe, Shin-ichi Matsumoto, Toshimasa Tanaka, Masashi Yamaguchi, Hiroyuki Kimura, Shoji Fukumoto.
Abstract
3-Metoxycarbonyl isoquinolone derivative 1 has been identified as a potent JNK inhibitor and significantly inhibited cardiac hypertrophy in a rat pressure-overload model. Herein, a series of isoquinolones with an imidazolylmethyl or a pyrazolylmethyl group at the 2-position were designed based on X-ray crystallographic analysis of the complex between the isoquinolone compound and JNK3, as wells as the relationship between compound lipophilicity (logD) and activity in a cell-based assay. The compounds prepared showed potent JNK1 inhibitory activities in a cell-based assay. Among them the isoquinolone derivative possessing 5-[(cyclopropylamino)carbonyl]-1-methyl-1H-pyrazole (16e) exhibited significant anti-hypertrophic activity at doses of more than 1mg/kg (po) in a pressure-overload model.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18313930 DOI: 10.1016/j.bmc.2008.02.028
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641